BioRestorative Therapies (BRTX) has released an update to notify the public and investors about a regulation fd disclosure.
The information detailed in this current report is not considered “filed” under Section 18 of the Securities Exchange Act of 1934 and therefore is not subject to the associated liabilities. This clarification is crucial for stock enthusiasts and casual investors alike, as it highlights the boundaries of legal responsibility for the content within the report.
For further insights into BRTX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
